US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
PMV Pharmaceuticals Inc (PMVP)
PMV Pharmaceuticals Inc (PMVP) ニュース

PMVP

PMV Pharmaceuticals (PMVP)

PMV Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PMVP

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/11	05 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/06/07	21 : 32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/30	20 : 00	GlobeNewswire Inc.	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/29	20 : 00	Business Wire	Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/29	20 : 00	GlobeNewswire Inc.	Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/09	21 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/09	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/05/09	21 : 00	GlobeNewswire Inc.	PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/03/27	21 : 00	GlobeNewswire Inc.	PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/03/19	05 : 01	GlobeNewswire Inc.	PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/03/01	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/03/01	06 : 01	GlobeNewswire Inc.	PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/02/26	22 : 00	GlobeNewswire Inc.	PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/24	23 : 01	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/23	06 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/23	06 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/19	06 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/19	06 : 01	GlobeNewswire Inc.	PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/12	06 : 18	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/06	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2024/01/06	06 : 01	GlobeNewswire Inc.	PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/11/09	22 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/11/09	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/11/09	22 : 00	GlobeNewswire Inc.	PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/10/13	06 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/10/13	01 : 30	GlobeNewswire Inc.	PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/10/12	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/10/12	01 : 00	GlobeNewswire Inc.	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/09/21	05 : 05	GlobeNewswire Inc.	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	NASDAQ:PMVP	PMV Pharmaceuticals Inc
2023/09/19	05 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PMVP	PMV Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:PMVP

1 2 3 4 5 6 7 8 次へ >>

Invesco QQQ Trust Series 1

BNP Paribas (QX)

JP Morgan Chase

US Dollar vs Euro

Gold vs US Dollar

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約